Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?

Oxaliplatin Plus Dual Inhibition of Thymidilate Synthase During Preoperative Pelvic Radiotherapy for Locally Advanced Rectal Carcinoma: Long-Term Outcome

“…Interestingly, a direct correlation between the dose of OXA (#85 mg/m 2 vs. >85 mg/m 2 ) actually delivered over 2 weeks and the activity of regimens in which OXA was combined with 5-FU (FOLFOX) has been reported in these patients (42). Moreover, preclinical studies have also shown that the radiosensitizing property of OXA is dose dependent, suggesting the existence of a threshold dose (14,41).…”

“…Moreover, OXA was reported to induce a prolonged cell accumulation into the G 2 /M phases (41). All these cell cycle perturbations could be crucial for increasing the sublethal damage of RT.…”

Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Multiplex Kinase Activity Profiling

“…Of note, in 2 recent randomized Phase III trials that have examined preoperative CRT with or without oxaliplatin in rectal cancer, the investigators were not able to demonstrate improved local tumor control in the oxaliplatin arm (35,36). We have also previously reported, using an experimental in vivo model of human colorectal carcinoma, that oxaliplatin did not improve the radiosensitizing effect of standard CRT (37). At present, the available clinical evidence supports the restricted use of oxaliplatin within investigational trials examining preoperative CRT, pending publication of patient survival data from the ongoing Phase III trials.…”

Update on Treatment Advances in Combined-Modality Therapy for Anal and Rectal Carcinomas

“…Oxaliplatin has also attracted interest in neoadjuvant therapy, in part because of its activity in treatment of colorectal tumors and also for its potential, but controversial, role as a radiosensitizer [31]. Results from the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase 3 trial were presented in preliminary form in 2009 [32].…”